Rare & Genetic · Clinical trials
Beta-Thalassaemia Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About beta-thalassaemia — and why its trials are hard
Beta-thalassaemia is an autosomal-recessive haemoglobinopathy caused by mutations in the HBB gene that reduce or abolish beta-globin chain synthesis, producing ineffective erythropoiesis, chronic haemolytic anaemia and iron overload. The transfusion-dependent (TDT) form requires lifelong red-cell transfusions and iron chelation, while non-transfusion-dependent (NTDT) disease causes intermittent anaemia and progressive organ damage. For decades management centred on transfusion, chelation (deferoxamine, deferasirox, deferiprone) and allogeneic haematopoietic stem-cell transplantation, the only established cure. The therapeutic landscape shifted with luspatercept (Reblozyl), an erythroid-maturation agent that reduces transfusion burden, and with gene-based cures: betibeglogene autotemcel (Zynteglo), an ex-vivo lentiviral beta-globin gene addition therapy, and exagamglogene autotemcel (Casgevy), a CRISPR-edited BCL11A therapy that reactivates fetal haemoglobin. These one-time therapies can free many patients from regular transfusions. Endpoints in trials emphasise transfusion-independence and reductions in transfusion volume. Supportive care, endocrine and cardiac surveillance for iron-related complications remain central even in the era of disease-modifying and curative options.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Luspatercept (Reblozyl) | 2019 | Adults with transfusion-dependent beta-thalassaemia requiring regular RBC transfusions | BELIEVE (phase 3, NEJM 2020) | ≥33% reduction in transfusion burden (with ≥2 units) over weeks 13-24 vs baseline | 21.4% of luspatercept patients vs 4.5% placebo achieved the primary endpoint |
| Betibeglogene autotemcel (Zynteglo) | 2022 | Adults and children with transfusion-dependent beta-thalassaemia (US approval) | HGB-207 (Northstar-2) / HGB-212 (Northstar-3) | Transfusion independence (mean Hb ≥9 g/dL without transfusion ≥12 months) | ~89% (32/36) of evaluable patients across studies achieved transfusion independence |
| Exagamglogene autotemcel (Casgevy) | 2024 | Transfusion-dependent beta-thalassaemia, age ≥12 years (CRISPR/Cas9 gene editing) | CLIMB THAL-111 | Transfusion independence ≥12 consecutive months (weighted mean Hb ≥9 g/dL) | ~91% (39/43) of evaluable patients achieved transfusion independence |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in beta-thalassaemia development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Sotatercept (ACE-011) — Phase 2 in beta-thalassaemia (NTDT/TDT) | Development for thalassaemia discontinued in favour of the related agent luspatercept | Overlapping mechanism and a more favourable efficacy/tolerability profile for luspatercept led the sponsor to prioritise luspatercept; sotatercept was redirected to pulmonary arterial hypertension |
Choosing the right endpoint
Primary endpoints that matter in beta-thalassaemia trials
- Transfusion burden reduction — Proportion achieving ≥33% (and ≥2 units) fewer RBC transfusions over a defined window; primary endpoint in BELIEVE for luspatercept
- Transfusion independence — Absence of transfusions for ≥12 months with maintained haemoglobin; key endpoint for gene therapies (beti-cel, exa-cel)
- Haemoglobin response — Rise in total/weighted-mean Hb, relevant in NTDT and as a component of transfusion-independence definitions
- Iron burden / chelation — Serum ferritin and liver iron concentration; reduced transfusions can lower iron overload and chelation needs
How iNGENū runs beta-thalassaemia trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Beta-Thalassaemia clinical trials — FAQs
Is a cure available for beta-thalassaemia?
How does luspatercept work?
Does luspatercept eliminate the need for transfusions?
Ready to discuss your beta-thalassaemia trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal